行情

OGEN

OGEN

ORAGENICS
AMEX

实时行情|Nasdaq Last Sale

0.4600
-0.0085
-1.81%
已收盘, 17:43 11/12 EST
开盘
0.4649
昨收
0.4685
最高
0.4720
最低
0.4590
成交量
26.27万
成交额
--
52周最高
1.670
52周最低
0.3500
市值
2,121.74万
市盈率(TTM)
-0.5945
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

OGEN 新闻

  • Oragenics Highlights Senior VP of Discovery Research, Martin Handfield, Will Be Featured Speaker At International Conference on Microbial Research and Applications Nov. 13, 2019
  • Benzinga.1天前
  • Oragenics, Inc. SVP of Discovery Research, Martin Handfield, Ph.D. to Be Featured Speaker at the International Conference on Microbial Research and Applications
  • Business Wire.1天前
  • Facebook将推出全新新闻服务
  • 亿欧网.10/26 03:25
  • Facebook推出全新新闻服务,部分内容由人工记者筛选
  • PingWest品玩.10/26 03:22

更多

所属板块

生物技术和医学研究
+0.28%
制药与医学研究
+0.27%

热门股票

名称
价格
涨跌幅

OGEN 简况

Oragenics, Inc. develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering. MU1140 is an antibiotic that is produced by the parent of the SMaRT strain. ProBiora3 is a blend of three naturally occurring strains of beneficial bacteria, including Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145. LPT3-04 is a compound, which is consumed in the human diet in small amounts and results in dose-dependent weight loss in experimental animal models.
展开

Webull提供Oragenics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。